SCHEMBL5285757

SCHEMBL5285757

[CH2]c1nn(-c2ccccc2)nc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.51
ADORA1 P30542 2/20 0.51
PKM P14618 2/20 0.51
ADORA3 P0DMS8 2/20 0.51
LMNA P02545 1/20 0.51
ADORA2A P29274 1/20 0.51
ADORA2B P29275 1/20 0.51
KAT2B Q92831 1/20 0.51
HPGD P15428 2/20 0.50
ABCG2 Q9UNQ0 1/20 0.41
ALDH1A1 P00352 2/20 0.40
MAPK1 P28482 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
TSHR P16473 1/20 0.40
MAPT P10636 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL416916 0.84 KDM4E (0.61) KDM4EADORA1PKMADORA3LMNA
Ammonia Solution, Strong SCHEMBL3507660 0.82 KDM4E (0.58) KDM4EADORA1PKMADORA3LMNA
SCHEMBL13523227 0.75 KDM4E (0.51) KDM4EADORA1PKMADORA3LMNA
SCHEMBL201295 0.75 LMNA (0.51) KDM4EADORA1PKMADORA3LMNA
SCHEMBL820842 0.73 KDM4E (0.50) KDM4EADORA1PKMADORA3LMNA
SCHEMBL18306187 0.73 KDM4E (0.50) KDM4EADORA1PKMADORA3LMNA
SCHEMBL2624396 0.72 KDM4E (0.49) KDM4EADORA1PKMADORA3LMNA
SCHEMBL27794740 0.72 KDM4E (0.49) KDM4EADORA1PKMADORA3LMNA
SCHEMBL12713296 0.72 KDM4E (0.49) KDM4EADORA1PKMADORA3LMNA
SCHEMBL5737641 0.72 KDM4E (0.49) KDM4EADORA1PKMADORA3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO claimed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US claimed
EP-2999338-B1 KNOWN AND NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES BAYER CROPSCIENCE AG (DE) 2017-07-12 EP disclosed
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 KDM4E 4305/4885ADORA1 4671/4885PKM 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.